Decoy oligodeoxynucleotides: A promising therapeutic strategy for inflammatory skin disorders

Basit Öğe Kaydı
dc.authoridKARAV, SERCAN/0000-0003-4056-1673
dc.contributor.authorMahjoubin-Tehran, Maryam
dc.contributor.authorRezaei, Samaneh
dc.contributor.authorKarav, Sercan
dc.contributor.authorKesharwani, Prashant
dc.contributor.authorSahebkar, Amirhossein
dc.date.accessioned2025-01-27T21:03:36Z
dc.date.available2025-01-27T21:03:36Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractChronic inflammatory skin conditions such as psoriasis and atopic dermatitis (AD) impose a significant burden on both the skin and the overall well-being of individuals, leading to a diminished quality of life. Despite the use of conventional treatments like topical steroids, there remains a need for more effective and safer therapeutic options to improve the lives of patients with severe skin conditions. Molecular therapy has emerged as a promising approach to address disorders such as atopic dermatitis, psoriasis, and contact hypersensitivity. One strategy to counteract the disease processes involves targeting the transcriptional process. A novel form of gene therapy utilizes double-stranded oligodeoxynucleotides (ODNs), also known as decoys, that contain cis-elements. By introducing these decoy ODNs through transfection, the cis-trans interactions are disrupted, leading to the inhibition of trans-factors from binding to the intrinsic cis-elements and thus regulating gene expression. In this review, we have summarized studies investigating the therapeutic effects of decoy ODNs on inflammatory skin diseases. Various transcription factors, including NF-kB, STAT6, HIF-1 alpha/STAT5, STAT1, and Smad, have been targeted and inhibited using designed decoy ODNs for the treatment of atopic dermatitis, psoriasis, hypertrophic scarring, and contact hypersensitivity. The findings of these studies confirm the significant potential of the decoy approach in the treatment of inflammatory skin diseases.
dc.identifier.doi10.1016/j.humimm.2024.111161
dc.identifier.issn0198-8859
dc.identifier.issn1879-1166
dc.identifier.issue6
dc.identifier.pmid39454315
dc.identifier.scopus2-s2.0-85207071292
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.humimm.2024.111161
dc.identifier.urihttps://hdl.handle.net/20.500.12428/27364
dc.identifier.volume85
dc.identifier.wosWOS:001343999400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofHuman Immunology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectAtopic dermatitis
dc.subjectDecoy
dc.subjectPsoriasis
dc.subjectTherapeutics
dc.subjectSkin diseases
dc.subjectInflammatory
dc.titleDecoy oligodeoxynucleotides: A promising therapeutic strategy for inflammatory skin disorders
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu